Brain Cancer Clinical Trials in Massachusetts

Showing 41-60 of 85 trials

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

NCT01986348

This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.

GlioblastomaGlioma

Karyopharm Therapeutics Inc76 participantsStarted Mar 2014

Boston, Massachusetts, United States • Boston, Massachusetts, United States • New York, New York, United States +3 more locations

COMPLETEDPHASE126 miles

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

NCT02311920

This phase I trial studies the safety and best dose of ipilimumab, nivolumab, or both in combination with temozolomide in treating patients with newly diagnosed glioblastoma or gliosarcoma. Monoclonal antibodies, such as ipilimumab and nivolumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known which combination is a better treatment for glioblastoma or gliosarcoma.

GliosarcomaSupratentorial Glioblastoma

National Cancer Institute (NCI)32 participantsStarted Apr 2015

San Francisco, California, United States • Atlanta, Georgia, United States • Baltimore, Maryland, United States +8 more locations

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Brain Cancer Trials in Other Cities

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Gliogene: Brain Tumor Linkage Study

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas

First in Patient Study for PF-06840003 in Malignant Gliomas

Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

UNITE Study: Understanding New Interventions With GBM ThErapy

Other Conditions in Massachusetts